
 
 
 
 
 
 
 
 
   
 1. A preventive or therapeutic agent when used for the prevention or treatment of psoriasis comprising interleukin-6 (N (IL-6) antagonist as an active ingredient wherein said IL-6 Santagonist is an antibody which is capable of blocking signal c-i transduction by IL-6. 
 
     
 2. The preventive or therapeutic agent according to claim eg 1, in which the IL-6 antagonist is an antibody against IL-6 receptor. 
 
     
 3. The preventive or therapeutic agent according to claim 2, in which the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor. 
 
     
 4. The preventive or therapeutic agent according to claim 3, in which the antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor. The preventive or therapeutic agent according to claim 3, in which the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor. 
 
     
 6. The preventive or therapeutic agent according to any one of claims 2-5, in which the antibody against IL-6 receptor is a recombinant antibody. 
 
     
 7. The preventive or therapeutic agent according to claim 4, in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody. 
 
     
 8. The preventive or therapeutic agent according to claim in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody. 
 
     
 9. The preventive or therapeutic agent according to any one of claims 2-4, in which the antibody against IL-6 receptor is a chimeric antibody or a humanized antibody against IL-6 receptor. P. OPERRASClaims12209340 la sp 324 doc-23/11/2006 0 37 z i 1 0. The preventive or therapeutic agent according to claim M 9, in which the humanized antibody against IL-6 receptor is a humanized PM-1 antibody. 
 
     
 11. Use of an interleukin-6 (IL-6) antagonist for the (N V 5 production of a preventive and therapeutic agent for psoriasis wherein said IL-6 antagonist is an antibody which is capable of C- blocking signal transduction by IL-6. S12. The use according to claim 11, in which the IL-6 e< antagonist is an antibody against IL-6 receptor. 
 
     
 13. The use according to claim 12, in which the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor. 
 
     
 14. The use according to claim 13, in which the antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor. The use according to claim 13, in which the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor. 
 
     
 16. The use according to any one of claims 12-15, in which the antibody against IL-6 receptor is a recombinant antibody. 
 
     
 17. The use according to claim 14, in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody. 
 
     
 18. The use according to claim 15, in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody. 
 
     
 19. The use according to any one of claims 12-14, in which the antibody against IL-6 receptor is a chimeric antibody or a humanized antibody against IL-6 receptor. The use according to claim 19, in which the humanized antibody against IL-6 receptor is a humanized PM-i antibody. 
 
     
 21. A method of preventing or treating psoriasis comprising administering an interleukin-6 (IL-6) antagonist to a subject wherein said IL-6 antagonist is an antibody which is capable of blocking signal transduction by IL-6. POPER\RASClaimN12209340 spa 324doc.2311 I/2006 38 z 22. The method according to claim 21, in which the IL-6 antagonist is an antibody against IL-6 receptor. 
 
     
 23. The method according to claim 22, in which the antibody against IL-6 receptor is a monoclonal antibody against (N V) 5 IL-6 receptor. 
 
     
 24. The method according to claim 23, in which the 9c antibody against IL-6 receptor is a monoclonal antibody against Shuman IL-6 receptor. pi 25. The method according to claim 23, in which the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor. 
 
     
 26. The method according to any one of claims 22-25, in which the antibody against IL-6 receptor is a recombinant antibody. 
 
     
 27. The method according to claim 24, in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody. 
 
     
 28. The method according to claim 25, in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody. 
 
     
 29. The method according to any one of claims 22-24, in which the antibody against IL-6 receptor is a chimeric antibody or a humanized antibody against IL-6 receptor. The method according to claim 29, in which the humanized antibody against IL-6 receptor is a humanized PM-1 antibody. 
 
     
 31. A preventive or therapeutic agent according to any one of claims 1-10 or use according to any one of claims 11-20 or a method according to any one of claims 21-30 substantially as hereinbefore described with reference to the Figures and/or Examples. 
 
   
 
 
 
 
 
 
 
 
